Track WHWK and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$263.01M
Enterprise Value$117.58M
Revenue (TTM)$7.14M
Net Income (TTM)-$20.60M
Free Cash Flow (TTM)-$97.98M
Financial Health
Cash$145.70M
Net Debt-$145.43M
Debt Ratio0
Debt to Equity0
Interest Coverage-
Valuation (TTM)
Price to Sales36.81
Price to Earnings-12.77
EV to EBITDA-1.07
Price to Book1.93
Price to Free Cash Flow-2.68
Margins (TTM)
Gross Profit Margin89.06%
EBITDA Margin-1545.09%
Operating Income Margin-1601.12%
Net Income Margin-288.26%
Free Cash Flow Margin-1371.38%
Returns (5Y Avg)
Return on Invested Capital-79.46%
Return on Assets-66.11%
Return on Equity-63.58%
Return on Total Capital-79.46%
Return on Capital Employed-78.87%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-13.29%
Diluted EPS-0.19%
Total Debt-96.04%
Capital Expenditures1000.00%
Free Cash Flow-97.41%
CAGR (3Y)
Revenue-22.27%
Diluted EPS38.43%
Total Debt-98.64%
Capital Expenditures7.53%
Free Cash Flow-99.72%
CAGR (1Y)
Revenue-72.50%
Diluted EPS205.37%
Total Debt-100.00%
Capital Expenditures-66.63%
Free Cash Flow-100.00%
$3.91+$0.12|+3.17%
52W High$5.50
52W Low$1.57
50D SMA$4.23
200D SMA$3.25
Volume288.08K
Whitehawk Therapeutics, Inc.
2 Headquarters Plaza, Morristown, NJ, United States, 07960
IPO
2017
Employees
29
Industry
Biotechnology
Sector
Healthcare
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 202611-11
0
Q1 20263-3
0
2-quarter cumulative
14 sells0 buys
Analyst Ratings
3 analysts covering
Hold100%recommend hold
Buy
0
Hold
3
Sell
0